V
Vicente Estrada
Researcher at Hospital Clínico San Carlos
Publications - 162
Citations - 5636
Vicente Estrada is an academic researcher from Hospital Clínico San Carlos. The author has contributed to research in topics: Medicine & Population. The author has an hindex of 28, co-authored 147 publications receiving 4020 citations. Previous affiliations of Vicente Estrada include Complutense University of Madrid.
Papers
More filters
Journal ArticleDOI
El ictus en pacientes muy ancianos: mitos y realidades
Sergio Serrano-Villar,Gema Fresco,Pedro Ruiz-Artacho,Ana Bravo,Cristina Valencia,Manuel Fuentes-Ferrer,Vicente Estrada,Jesús Porta-Etessam +7 more
TL;DR: Los sujetos muy ancianos ingresados por ictus isquemico reciben menores recursos diagnosticos y terapeuticos, y en nuestro estudio the edad no fue un factor independiente para la mortalidad.
Journal ArticleDOI
Underlying heart diseases and acute COVID-19 outcomes.
Iván J. Núñez-Gil,Antonio Fernández-Ortiz,Charbel Maroud Eid,Jia Huang,Rodolfo Romero,Víctor Manuel Becerra-Muñoz,Aitor Uribarri,Gisela Feltes,Daniela Trabatoni,Inmaculada Fernández-Rozas,María C Viana-Llamas,Martino Pepe,Enrico Cerrato,Maurizio Bertaina,Thamar Capel Astrua,Emilio Alfonso,Alex F Castro-Mejía,Sergio Raposeiras-Roubín,Fabrizio D'Ascenzo,Carolina Espejo Paeres,Jaime Signes-Costa,Alfredo Bardají,Cristina Fernández-Pérez,Francisco Marín,Óscar Fabregat-Andrés,Ibrahim Akin,Vicente Estrada,Carlos Macaya +27 more
TL;DR: An underlying heart disease is an adverse prognostic factor for patients suffering COVID-19 and would benefit from maintaining treatment with angiotensin converting enzyme inhibitors or angiotENSin receptor blockers during in-hospital stay.
Journal ArticleDOI
Association of HIV-Infection and antiretroviral therapy with levels of endothelial progenitor cells and subclinical atherosclerosis.
Dulcenombre Gómez-Garre,Vicente Estrada,Adriana Ortega-Hernández,Paloma Muñoz-Pacheco,Sergio Serrano-Villar,M. Avila,Manuel Fuentes-Ferrer,Teresa Tejerina,Arturo Fernández-Cruz +8 more
TL;DR: Antiretroviral therapy (ART)-treatment was identified as the main predictive value for low CD34+/KDR+ cells and high CD14+/Endoglin+ cells after adjustment by cardiovascular risk factors and HIV-related characteristics.
Journal ArticleDOI
Clinical presentation, therapeutic approach, and outcome of young patients admitted for COVID-19, with respect to the elderly counterpart.
Martino Pepe,Charbel Maroun-Eid,Rodolfo Romero,Ramón Arroyo-Espliguero,Inmaculada Fernández-Rozas,Álvaro Aparisi,Víctor Manuel Becerra-Muñoz,Marcos García Aguado,Gaetano Brindicci,Jia Huang,Emilio Alfonso-Rodríguez,Alex F Castro-Mejía,Serena Favretto,Enrico Cerrato,Paloma Albiol,Sergio Raposeiras-Roubín,Oscar Vedia,Gisela Feltes Guzman,Ana Carrero-Fernández,Clara Perez Cimarra,Luis Buzón,Jorge Luis Jativa Mendez,Mohammad Abumayyaleh,Miguel Corbí-Pascual,Carlos Macaya,Vicente Estrada,Palma Luisa Nestola,Giuseppe Biondi-Zoccai,Iván J. Núñez-Gil +28 more
TL;DR: In this paper, the authors investigated the baseline characteristics, in-hospital treatment, and outcomes of a wide cohort of patients younger than 65 years admitted for coronavirus disease 2019 (COVID-19).
Journal ArticleDOI
Preclinical and randomized phase I studies of plitidepsin in adults hospitalized with COVID-19
J.F. Varona,Pedro Landete,Jose A. Lopez-Martin,Vicente Estrada,Roger Paredes,Pablo Guisado-Vasco,L. Fernández de Orueta,Miguel Torralba,Jesús Fortún,R. Vates,José Barberán,Bonaventura Clotet,Julio Ancochea,Daniela Candia Carnevali,Noemi Cabello,L Porras,Paloma Gijón,Alfonso Monereo,Daniel Abad,Sonia Zuñiga,Isabel Sola,Jordi Rodon,Júlia Vergara-Alert,Nuria Izquierdo-Useros,Salvador Fudio,Maria J. S. L. Pontes,Beatriz de Rivas,Patricia Girón de Velasco,Antonio Nieto,Javier Gomez,Pablo Aviles,Rubin Lubomirov,Alvaro Belgrano,Belén Sopesén,Kris M. White,Romel Rosales,Soner Yildiz,Ann-Kathrin Barbara Reuschl,Lucy Thorne,Clare Jolly,Greg J. Towers,Lorena Zuliani-Alvarez,Mehdi Bouhaddou,Kirsten Obernier,Brian McGovern,Mariano Rodriguez,Luis Enjuanes,J. M. Fernández-Sousa,Nevan J. Krogan,Jose Jimeno,Adolfo García-Sastre +50 more
TL;DR: It is shown that plitidepsin distributes preferentially to lung over plasma, with similar potency against across several SARS-CoV-2 variants in preclinical studies, and has a favorable safety profile in patients with COVID-19.